Considering the influence of tumors on the thrombus process and inflammation intervention during thrombus evolution, it is reasonable to speculate that SHP2 inhibition triggering tumor suppression could ameliorate the thrombi burden. This evidence concerns the gene PTPN11 and neoplasm.